Chiesi.
Company
- Reports this week
- 0
- Active events
- 0
- Connections
- 20
What's happening
Earlier this month
One to three months ago
-
Chiesi presented abstracts at the SSIEM congress in Helsinki, Finland.Some support2 reports
-
Gossamer Bio regained full global rights from Chiesi, while facing FDA review issues and authorizing a reverse split for Nasdaq compliance.Some support2 reports
-
Pfizer reported $5.6 million in sales to Chiesi and announced changes to its Chief Financial Officer.Some support2 reports
-
Gossamer Bio and Chiesi announced a joint collaboration to develop seralutinib under global collaboration.Some support2 reports1 development inside
-
An analyst suggested that a specific stock, involving Chiesi, could be the next major success story after Nvidia.Some support1 report
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Chiesi this week
News at the entities that move Chiesi most-
European Medicines Agency StructuralBoth the FDA and the European Medicines Agency are evaluating NervGen's lead therapeutic candidate.Moves Chiesi
-
Pfizer OperationalDave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Moves Chiesi
-
Nvidia Mentioned togetherNvidia is expanding its platform deployment across major cloud providers, including Google Cloud and Microsoft Azure.Moves Chiesi
-
Singapore Shared contextTemasek acquired a stake in FSI's management company in Singapore.Moves Chiesi
-
Helsinki Shared contextOutokumpu is a company headquartered in Helsinki, Finland.Moves Chiesi
-
Finland Shared contexteasyJet is launching new winter routes to destinations including Finland, Hurghada, Copenhagen, Barcelona, and Berlin.Moves Chiesi
Connections
The 10 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Gossamer Bio (United States) Operational
Gossamer Bio and Chiesi maintain a strategic partnership involving joint development and financial collaboration.
-
Pfizer Operational
The relationship is characterized by a partnership structure where Chiesi contributes to global product penetration, while Pfizer provides steady market demand for Chiesi's products.
-
European Medicines Agency Structural
Chiesi seeks validation for its products from the European Medicines Agency for market access in Europe.
-
IMPULSE Operational
Chiesi provides support for the Impulse initiative.
-
CRISPR Therapeutics Mentioned together
The entities are co-mentioned as mid-to-mega-cap healthcare stocks within the market context.
-
UCB Mentioned together
The entities are co-mentioned as participants in broader life sciences industry discussions.
-
Nvidia Mentioned together
An analyst compared the stock potential of Chiesi to Nvidia.
-
Singapore Shared context
Chiesi operates within Singapore by supporting local initiatives like NSG Bio.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
2 eventsJuly 2026
1 eventShow 1 earlier month
June 2026
4 events- Pfizer reported $5.6 million in sales to Chiesi and announced changes to its Chief Financial Officer.
- Gossamer Bio and Chiesi announced a joint collaboration to develop seralutinib under global collaboration.
- Chiesi gained control of KalVista's headquarters and lab space.
- Hansa Biopharma, Chiesi, and UCB participated in life sciences discussions in Lisbon.